Conference Coverage

Cisplatin-gemcitabine is highly active in BRCA/PALB2+ pancreatic cancer


 

REPORTING FROM THE 2020 GI CANCERS SYMPOSIUM

Study details

The trial was conducted among 52 patients with untreated locally advanced or metastatic pancreatic ductal adenocarcinoma. Fully 94% had a BRCA mutation, while the rest had a PALB2 mutation, according to data reported at the symposium, sponsored by the American Gastroenterological Association, the American Society of Clinical Oncology, the American Society for Radiation Oncology, and the Society of Surgical Oncology.

The response rate – the trial’s primary endpoint – was 65.2% with cisplatin-gemcitabine alone and 74.1% with cisplatin-gemcitabine plus veliparib (P = .55), with both arms far exceeding not only the 10% prespecified as “acceptable,” but also the 30% prespecified as “promising.” The respective disease control rates were 78.3% and 100% (P = .02).

Median progression-free survival was 9.7 months with chemotherapy alone and 10.1 months with chemotherapy plus the PARP inhibitor (P = .73). “If you reference an unselected population, that would be about 5 to 7 months,” Dr. O’Reilly noted. Median overall survival was 16.4 months and 15.5 months, respectively (P = .6). For the entire trial cohort, the 2-year overall survival rate was 30.6% and the 3-year overall survival rate was 17.8%.

“The combination came at the expense of hematologic toxicity,” Dr. O’Reilly said, with patients given veliparib having higher rates of grade 3 or 4 neutropenia (48% vs. 30%), thrombocytopenia (55% vs. 9%), and anemia (52% vs. 35%).

In an exploratory analysis among all patients receiving 4 or more months of chemotherapy and then continuing on or starting a PARP inhibitor as their next therapy, without disease progression, median overall survival was 23.4 months, very similar to what was seen in the POLO trial, she noted.

Dr. O’Reilly disclosed that she has ties with Vesselon, Polaris, and CytomX, and that her institution receives grant/research support from Celgene, Sanofi, Genentech-Roche, AstraZeneca, BMS, Silenseed, MabVax, Halozyme, and Acta Biologica. The trial was funded by the Lustgarten Foundation, the David M. Rubenstein Center for Pancreatic Cancer Research, the Reiss Family Foundation, the National Cancer Institute’s Cancer Therapy Evaluation Program, and NCI grants. Dr. Schilsky disclosed that he has no conflicts of interest.

SOURCE: O’Reilly EM et al. 2020 GI Cancers Symposium. Abstract 639.

Pages

Recommended Reading

Platinum-based therapy superior in study of upper GI tumors
MDedge Hematology and Oncology
Data support maintenance in metastatic colorectal cancer
MDedge Hematology and Oncology
Dual HER2 therapy added to CRT for esophageal cancer is tolerable, active
MDedge Hematology and Oncology
ctDNA outmatches CEA for detection of colorectal cancer recurrence
MDedge Hematology and Oncology
Unique T cell populations pinpointed in hepatocellular carcinoma tissue
MDedge Hematology and Oncology
FDA approves avapritinib for adults with GIST with PDGFRA mutation
MDedge Hematology and Oncology
Eradicating H. pylori may cut risk of gastric cancer
MDedge Hematology and Oncology
Three or more nonadvanced adenomas no longer spell increased CRC risk
MDedge Hematology and Oncology
Blood test may advance diagnosis of GI cancers
MDedge Hematology and Oncology
Sociodemographic disadvantage confers poorer survival in young adults with CRC
MDedge Hematology and Oncology